Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 1999, p. 1947-1954, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Emergence of Drug-Resistant Populations of
Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral
Nucleoside Lamivudine
Tianlun
Zhou,1,2
Jeffry
Saputelli,1
Carol E.
Aldrich,1
Manon
Deslauriers,3
Lynn D.
Condreay,3 and
William
S.
Mason1,*
Fox Chase Cancer Center, Philadelphia,
Pennsylvania 191111; Biomedical Graduate
Studies, University of Pennsylvania, Philadelphia, Pennsylvania
191042; and Department of Virology,
Glaxo Wellcome, Inc., Research Triangle Park, North Carolina
277093
Received 1 February 1999/Returned for modification 31 March
1999/Accepted 24 May 1999
Lamivudine [(
)-
-L-2',3'-dideoxy-3'-thiacytidine]
reduces woodchuck hepatitis virus (WHV) titers in the sera of
chronically infected woodchucks by inhibiting viral DNA synthesis.
However, after 6 to 12 months, WHV titers begin to increase toward
pretreatment levels. Three WHV variants with mutations in the active
site of the DNA polymerase gene are present at this time (W. S. Mason et al., Virology 245:18-32, 1998). We have asked if these mutant viruses were responsible for the lamivudine resistance and if their
emergence caused an immediate rise in virus titers. Cell cultures
studies implied that the mutants were resistant to lamivudine. Emergence of mutant WHV was not always associated, however, with an
immediate rise in virus titers in the serum. One of the three types of
mutant viruses became prominent in serum up to 7 months before titers
in serum actually began to increase, at a time when wild-type virus was
still predominant in the liver. The two other mutants did not show this
behavior but were detected in serum and liver later, just at the time
that virus titers began to rise. A factor linking all three mutants was
that a similar duration of drug administration preceded the rise in
titers, irrespective of which mutant ultimately prevailed. A simple
explanation for these results is that the increase in virus titers
following emergence of drug-resistant mutants can occur only as the
preexisting wild-type virus is cleared from the hepatocyte population,
allowing spread of the mutants. Thus, prolonged suppression of virus
titers in the serum may sometimes be a measure of the stability of
hepatocyte infection rather than of a successful therapeutic outcome.
*
Corresponding author. Mailing address: Fox Chase Cancer
Center, 7701 Burholme Ave., Philadelphia, PA 19111. Phone: (215)
728-2402. Fax: (215) 728-3616. E-mail:
ws_mason{at}fccc.edu.
Antimicrobial Agents and Chemotherapy, August 1999, p. 1947-1954, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Menne, S., Butler, S. D., George, A. L., Tochkov, I. A., Zhu, Y., Xiong, S., Gerin, J. L., Cote, P. J., Tennant, B. C.
(2008). Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother.
52: 3617-3632
[Abstract]
[Full Text]
-
Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discotto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., Colonno, R. J.
(2004). Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine. Antimicrob. Agents Chemother.
48: 3498-3507
[Abstract]
[Full Text]
-
Foster, W. K., Miller, D. S., Marion, P. L., Colonno, R. J., Kotlarski, I., Jilbert, A. R.
(2003). Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection. Antimicrob. Agents Chemother.
47: 2624-2635
[Abstract]
[Full Text]
-
Walters, K.-A., Tipples, G. A., Allen, M. I., Condreay, L. D., Addison, W. R., Tyrrell, L.
(2003). Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. Antimicrob. Agents Chemother.
47: 1936-1942
[Abstract]
[Full Text]
-
Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P., Mason, W. S.
(2002). Mutations of the Woodchuck Hepatitis Virus Polymerase Gene That Confer Resistance to Lamivudine and 2'-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. J. Virol.
76: 1213-1223
[Abstract]
[Full Text]
-
Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S., Hantz, O., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F.
(2001). Antiviral Activity of {beta}-L-2',3'-Dideoxy-2',3'-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrob. Agents Chemother.
45: 1065-1077
[Abstract]
[Full Text]
-
Zhu, Y., Yamamoto, T., Cullen, J., Saputelli, J., Aldrich, C. E., Miller, D. S., Litwin, S., Furman, P. A., Jilbert, A. R., Mason, W. S.
(2001). Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis. J. Virol.
75: 311-322
[Abstract]
[Full Text]
-
Zhou, T., Guo, J.-T., Nunes, F. A., Molnar-Kimber, K. L., Wilson, J. M., Aldrich, C. E., Saputelli, J., Litwin, S., Condreay, L. D., Seeger, C., Mason, W. S.
(2000). Combination Therapy with Lamivudine and Adenovirus Causes Transient Suppression of Chronic Woodchuck Hepatitis Virus Infections. J. Virol.
74: 11754-11763
[Abstract]
[Full Text]
-
Zhang, Y.-Y., Summers, J.
(2000). Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus Infection. J. Virol.
74: 5257-5265
[Abstract]
[Full Text]